The Motley Fool··Geoffrey SeilerHims & Hers Surges 40% on Novo Nordisk Deal, But Valuation Concerns Linger
Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.
NVOHIMSGLP-1 drugstelemedicine